Infection by the hepatitis B virus (HBV) is one of the main etiologies of hepatocellular carcinoma (HCC). During chronic infection, HBV DNA can integrate into the human genome, and this has been postulated as a possible mechanism of HBV-induced HCC. In this study we used 2199 HBV integration sites from Dr.VIS v2.0 and mapped them to the human genome (hg19) to obtain viral integration sites (VIS) related to protein-coding and non-protein-coding genes. In total, we found 1,377 and 767 VIS within close proximity to protein coding genes and noncoding genes, respectively. Genes affected more than two times included 23.1% of protein-coding genes and 24.7% of long noncoding RNAs (lncRNA). Only 4.8% of VIS were shared between HCC and non-tumor tissues. HBV integrations were more common in chromosomes 5, 8, 10, and 19 in HCC tissue and chromosomes 1 and 2 in nontumorous tissue. The number of integration sites on each chromosome correlated with the number of fragile sites in nontumorous tissue but not in HCC tissue. Functional enrichment analysis of the protein-coding genes containing or in close proximity to HBV integration sites in HCC tissue showed an enrichment of cancer related gene ontology terms. Additionally, the most frequently associated lncRNA genes were related to telomere maintenance, protein modification processes, and chromosome localization. Thus, HBV may have preferred integration sites in the human genome that serve a critical role in HCC development. These results show that HCC treatment may benefit from the development of next generation anti-viral therapies.
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third leading cause of cancer-related mortality worldwide. [1] [2] [3] More than 50% of HCCs are attributed to chronic infection by hepatitis B virus (HBV). [4] [5] [6] This is especially true in China, Southeast Asia, and sub-Saharan Africa, where there is a 25-to 37-fold increased risk of developing HCC in HBsAg (the surface antigen of HBV) positive patients compared with non-infected patients. 7 Even patients with low HBV load have increased risk of HCC development. 8 Changes in cell behavior resulting from altered expression of the genes proximal to the specific site of HBV integration is one hypothesis for the HBV associated HCC. [9] [10] [11] During chronic infection, HBV DNA integrates into the human genome and alters endogenous gene expression and/or function and chromosome stability. The phenomenon of HBV integration was first identified in the 1980s, [12] [13] [14] and subsequently, substantial work was conducted on the distribution of HBV integration sites and their functional role in tumorigenesis. However, due to the technical limitations, most traditionally identified HBV integration sites were close to Alu elements and not recurrent.
shown that fragile sites are hotspots of cancer breakpoints. 19, 20 Common fragile sites are defined as sites with a >5% break frequency in the normal population. To date, 245 common fragile sites are listed in NCBI, and these are regarded as part of normal chromosomal structure. A previous study showed that miRNA genes are frequently located at cancer associated regions or fragile sites. 21 Additionally, some common fragile site are preferred sites for plasmid and viral integration. 19, 20 Long noncoding RNAs (lncRNAs) are a class of RNAs containing over 200 nucleotides but lacking protein-coding open reading frames. Less than 2% of genes in the human genome encode proteins, while the majority are transcribed into non-coding RNAs. [22] [23] [24] However, few studies have focused on the relationship between sites of HBV integration and lncRNAs. To comprehensively study viral integration, we collected published data from Dr.VIS v2.0-an updated database of human disease-related viral integration sites (VIS) from highthroughput deep sequencing. 26 Based on our previous work, we re-annotated the HBV integration sites to study their distribution in HCC and non-tumorous tissues.
Material and Methods

Data preparation
HBV integration sites were downloaded from the Dr.VIS v2.0 database. 26 The known fragile sites were obtained from Mrasek's research 27 (Supporting Information Table S3 ). Function information for lncRNAs were obtained from the NON-CODE v4 database. 28 
Annotation of VIS-related genes
The human genome (hg19) was downloaded from RefSeq and NONCODE v4 databese. 28 The HBV integration sites listed in the Dr.VIS v2.0 database were then mapped onto the human genome. Genes with transcription start sites within 1 Mb from VIS were defined as VIS-related genes.
Gene functional enrichment analysis
VIS-related protein-coding genes were uploaded to DAVID 29 to perform gene ontology (GO) and KEGG pathway enrichment analyses. All human genes were used as a background gene list. The enrichment results were visualized using the Enrichment Map plug-in for Cytoscape. 30 
Statistical analysis
Statistical analyses were performed using R 3.1.3 (R Foundation for Statistical Computing, Vienna, Austria). The distribution of integration sites was visualized using OmicCircos R package. 31 The Pearson correlation between the number of fragile sites and number of integration sites on each chromosome was estimated using the function cov and the correlation matrix was visualized with psych R package.
Results
Distribution of viral integration sites
To investigate the distribution of HBV integration sites, we surveyed the Dr.VIS v2.0 database, which contained 2,199 non-repetitive HBV integration sites, including 1,409 sites involved in HCC and 790 sites from non-tumorous liver tissue (Supporting Information Table S1 ). We mapped the HBV integration sites, as reported in the Dr.VIS v2.0 database, to the human reference genome (hg19). Genes with transcription start sites closest to the HBV integration sites were defined as integration-targeted genes. Protein-coding genes were annotated to the NCBI RefSeq database and noncoding genes were annotated to the NONCODE v4 database.
In total, we found 1,377 integration-targeted protein-coding genes and 767 integration-targeted non-coding genes as well as 115 integration sites that we failed to annotate (Fig. 1 , Supporting Information Table S2 ). Analysis of the distribution of HBV integration sites on each chromosome showed the distributions to be quite different for HCC and non-tumorous tissues. First, the total number of VIS in tumorous tissues was nearly twofold higher than non-tumorous tissue. Moreover, the distribution of VIS on each chromosome was quite different. In HCC tissues, chromosomes 5, 8, 10, and 19 were the most frequent sites of HBV integration, harboring over 100 integration sites. While in non-tumorous tissue, HBV was more often found in chromosomes 1 and 2 (Fig. 2) . When we analyzed the category of the integration-targeted genes, HBV was found to integrate predominantly into non-coding regions of chromosome 10, What's new? During chronic infection, the hepatitis B virus (HBV) can integrate into chromosomal DNA, possibly inducing hepatocellular carcinoma (HCC). In this study, the authors found that the HBV-integration pattern in chromosomes of HCC cells was distinctly different than that in normal liver tissue. For example, in HCC cells, the virus had often integrated close to genes that regulate important oncogenic pathways. In addition, the study identified several novel HBV-integration hotspot long noncoding RNAs (lncRNAs), which were related to telomere maintenance and chromosome localization.
and coding regions of chromosomes 5, 8, and 19 in HCC tissues (Fig. 2) . While in non-tumorous tissues, both hotspots on chromosomes 1 and 2 were in regions harboring the most protein-coding genes.
To explore the relationship between fragile sites and HBV integration, we calculated the number of fragile sites and HBV integration sites on each chromosome and calculated Pearson correlation coefficients in HCC and non-tumorous tissues. In tumor tissue, we found that the total number of integration sites and integration-targeted coding genes showed a good correlation with the number of fragile sites, while the number of integration-targeted non-coding genes had a poor correlation with the number of fragile sites (Fig. 3 , Supporting Information Table S3 ). However, in non-tumorous tissue, we found that the distribution of VIS was significantly correlated with the number of fragile sites on each chromosome.
Functional annotation of integration-targeted genes
A number of studies have suggested that HBV integration participates in tumorigenesis by affecting gene expression in "cis" or in "trans", and several frequently targeted genes have been reported. In our analysis, the top five high frequency integration-targeted protein-coding genes in HCC tissues were TERT, MLL4, KMT2B, CCNE1 and FN1. Moreover, 28.6% (161 of 562) of the integration-targeted protein-coding genes had two or more integration sites (Fig. 4a) . However, non-tumorous tissues had a different set of frequently targeted protein-coding genes; the top five sites were FN1, CSMD1, PRC1, CTLA4 and CTDSPL2 and only 15.3% (61 of 397) of protein-coding genes were involved in HBV integration two times or more (Fig. 4b) .
To gain insight into the functional role of the frequently integrated protein-coding genes, we further conducted GO and KEGG pathway enrichment analyses. GO enrichment analysis of the frequently targeted protein-coding genes from HCC tissues showed that they are related to transcriptional, cell cycle, apoptotic and cytoskeletal regulation (Supporting Information Fig. S1 ). KEGG pathway enrichment analysis showed that three targeted genes were enriched in TGF-b signaling pathway (Supporting Information Table S4 ). GO enrichment analysis of the 61 most frequently targeted genes from non-tumorous samples showed they were enriched in regulators of apoptosis, transcription and phosphorus metabolism. No cancer-related pathways were enriched in these samples.
To further obtain insight into the functional characteristic of VIS protein coding genes, we screened the DriverDB v2 database 32 for the HCC driver genes. As a result, we identified 37 and 36 driver genes in HCC tissue and non-tumor tissue respectively (Supporting Information Fig. S2 , Table S5 ). Only 12.3% (8 of 65) of genes were shared between HCC tissue and non-tumor tissue.
Recent studies have revealed that lncRNA genes can serve as critical regulatory molecules in tumor genesis. In our analysis, we annotated 315 and 226 lncRNA genes from HCC and nontumorous tissues, respectively. In HCC tissue, the top five most frequently targeted lncRNA genes were NONHSAG005670, NONHSAG005669, NONHSAG005672, NONHSAG005676 and Figure 3 . Correlation between number of fragile sites and virus integration sites on each chromosome in both HCC tissue (a1-a3) and nontumorous tissue (b1-b3). In each scatterplot, x-axis represents the number of fragile sites. y-axis represents number of total integration sites (a1, b1), number of VIS-related protein coding genes (a2, b2), number of VIS-related non-coding genes (a3, b3). NONHSAG013941; nine lncRNA genes were integrated five times or more. However, only NONHSAG055279 was integrated four times in non-tumorous tissue (Supporting Information  Table S6 ). We then explored the NONCODE v4 database for functional annotation of these lncRNA genes, finding that theses lncRNA genes were related to telomere maintenance, protein modification processes and chromosome localization (Supporting Information Fig. S3 , Table S6 ).
Discussion
Many recent studies have investigated HBV integration and its role in HCC development, with the knowledge that integration can affect expression of nearby human genes. In this study, 2,199 HBV integration sites were analyzed to uncover the distribution pattern of HBV integration in HCC and non-malignant tissue.
In accordance with previous reports, our data showed that the number of HBV integration sites in HCC was nearly as two times the number found in non-tumorous tissue. 9, 33 Moreover, among the lists of integration-targeted genes, only a few (4.8%) were shared between HCC and non-tumorous tissues. This suggests that specific integration sites may contribute to HCC development. The distribution of HBV integration sites on each chromosome in HCC and nontumorous tissue was also quite different. In contrast to the previous studies of Ding et al. 10 and Toh et al., 11 which reported a predominance of HBV integration sites on chromosomes 10 and 17 in tumor tissues, we found hot spots for HBV integration on chromosomes 5, 8, 10 and 19. More than 100 integration sites were identified on these chromosomes. However, totally different with tumor tissue, chromosome 1 and 2 are more favored in non-tumor tissue.
According to our analysis, HBV integration was randomly dispersed throughout the human genome except for a few high frequency integration sites neighboring genes such as TERT, MLL4 and CCNE1, which was contrary to a previous report. 9, 34 Our data also showed that the number of HBV integration sites correlated with the number of the fragile sites, especially in non-tumorous tissue. Fragile sites are specific chromosomal regions that show gaps on metaphase spreads. Consequently, they are more likely to be the perfect break points that allow for HBV integration. Similarly, Li et al. 35 reported that HBV integration was more likely to occur in genic regions and gene dense regions where there is higher replicative stress and a looser secondary structure that is easier to break, and thus, may provide the cohesive ends for non-homologous end joining (NHEJ) with HBV DNA. Moreover, Ueda et al. found that HBV integration in the woodchuck model also occurred in specific genomic regions. Taken together, HBV integration may preferentially occur in distinct regions of human genome, 36 but the detailed mechanism of this process still need further exploration.lncRNA genes are critical regulatory molecules in HCC development. HBV integration may generate viral-human fusion transcripts that participate in HCC development. For example, Chi-Chiu Lau et al. identified a viral-human chimeric transcript HBx-LINE1 that can act as a lncRNA to activate Wnt signaling, which further promotes HCC formation. 37 By conducting a comprehensive analysis of 50 RNA-Seq datasets from HBV positive HCC tissues, Dong et al. found an HBV-MLL4 fusion transcript in 18% (8 of 44) of samples, and they also demonstrated that samples containing this fusion transcript had a distinct gene expression profile. 38 In our analysis, we found 541 VIS close to lnc RNA genes. The lncRNA genes most frequently associated with VIS were related to telomere maintenance, protein modification processes and chromosome localization. Therefore, these HBV integrations may affect expression of nearby lncRNA genes or form lncRNAlike chimeric transcripts that participate in malignant transformation. Together, these findings suggest there may be a benefit from a renewed effort into developing next generation anti-viral drugs to stop HCC.
